ClinicalTrials.gg
Active, not recruitingNCT07238114LIVERIPAUpdated Mar 4, 2026

Liver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk Factors

An observational study in Liver Cirrhosis, Viral Pneumonia and Fungal Infection, sponsored by Universitaire Ziekenhuizen KU Leuven. Active, not recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
450
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Liver Cirrhosis with a site in Belgium — 11 open to participants now, 13 under way, 2 of them phase 3. Liver Cirrhosis · Belgium.

Planned enrollment
9th of 17
450 · median 450
Started
2025
with 1 other
Observational
17 of 41
8 open now
Primary completion
2027-07
later than 6 of 12 live
Registered
38th of 41
by date
Lead sponsor
2 of 41
Universitaire Ziekenhuizen KU Leuven

Among the 41 studies in Liver Cirrhosis with a site in Belgium, this one is the 9th largest by planned enrollment of the 17 observational ones that give a count, is one of 2 that started in 2025, is one of 17 observational ones, reaches primary completion later than 6 of the 12 other live ones, and was the 38th registered.

Liver Cirrhosis

1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

11 of the 41 studies in Liver Cirrhosis with a site in Belgium are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Liver Cirrhosis with a site in Belgium, or all of them as a file.
02

Study summary

Invasive pulmonary aspergillosis (IPA) is a life-threatening fungal infection of the respiratory system, caused by a specific fungus called Aspergillus species. It is already known that patients with a weakened immune system are at higher risk of developing this disease. Recently, it has also been shown that patients with viral pneumonia (such as influenza or COVID-19) and patients with liver cirrhosis who are admitted to the intensive care unit are also vulnerable to this infection.

This study aims to better define the epidemiology, clinical risk factors, outcomes, and treatment of IPA in ACLF patients admitted to the ICU. By combining clinical data with histological findings from autopsies, the study seeks to improve diagnostic accuracy, risk prediction, and timely initiation of antifungal therapy.

03

Conditions studied

  • Liver Cirrhosis
  • Viral Pneumonia
  • Fungal Infection
  • Invasive Pulmonary Aspergillosis
  • Intensive Care Medicine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population consists of patients with known or suspected liver cirrhosis who were admitted to the Medical ICU of UZ Leuven.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All adults (≥ 18 years old)
  • Chronic liver disease
  • Admission to the Medical Intensive Care Unit of University Hospitals of Leuven

Exclusion criteria

Exclusion Criteria:

  • Patients \< 18 years
  • Recent history of invasive pulmonary aspergilosis and/or invasive candidiasis (\<1 month before ICU admission) and/or active treatment for IPA and/or invasive candidiasis
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
450 participants (estimated)
Patient registry
No

Groups and cohorts

  • ICU patients with liver cirrhosis and IPA

    The study population includes patients with confirmed or suspected liver cirrhosis who were admitted to the Medical ICU of UZ Leuven. Invasive pulmonary aspergillosis (IPA) is a life-threatening fungal infection, historically seen in severely immunocompromised patients. In recent years, it has also been increasingly recognized in ICU patients without classic immunosuppression, including those with viral pneumonia (e.g., influenza, COVID-19) and those with liver cirrhosis and acute-on-chronic liver failure (ACLF).

  • ICU patient with liver cirrhosis without IPA

    The study population consists of patients with known or suspected liver cirrhosis who were admitted to the Medical ICU of UZ Leuven.

06

What researchers measure

Primary outcomes

  1. IPA incidence

    The incidence of proven invasive pulmonary aspergillosis (IPA) in critically ill cirrhotic patients will be assessed. Routinely used biochemical and microbiological tests (such as galactomannan and Aspergillus PCR) will be performed on blood and BAL samples stored in the biobank to identify affected patients.

    Time frame: From the date of ICU admission until ICU discharge, approximately 7 days

  2. Identifying whether ACLF is an independent risk factor for IPA in EORTC-negative critically ill patients

    The occurrence of IPA will be compared between an ACLF EORTC-negative cohort and a non-ACLF cohort

    Time frame: From the date of ICU admission until ICU discharge, approximately 7 days

Secondary outcomes

  1. Clinical characteristics of IPA

    Baseline characteristics, organ failures, organ support, outcome parameters

    Time frame: From the date of ICU admission until ICU discharge, approximately 7 days

  2. Radiological characteristics of IPA

    Chest CT

    Time frame: From the date of ICU admission until ICU discharge, approximately 7 days

  3. Mycological characteristics of IPA

    Galactomannan testing, Aspergillus PCR, mycological culture

    Time frame: From the date of ICU admission until ICU discharge, approximately 7 days

  4. Impact of IPA on length of ICU stay

    Time frame: From the date of ICU admission until ICU discharge, approximately 7 days

  5. Impact of IPA on length of hospital stay

    Time frame: From the date of ICU admission until hospital discharge, approximately 36 days

  6. Impact of IPA on mortality

    Time frame: From ICU admission until 90 days post-admission

  7. Impact of IPA on liver transplant eligibility

    Time frame: From the date of ICU admission until ICU discharge, approximately 7 days

  8. Impact of IPA on liver transplant delisting

    Time frame: From the date of ICU admission until ICU discharge, approximately 7 days

  9. Histological characteristics of IPA using tissue staining

    Histological characteristics of IPA in critically ill cirrhotic patients will be analyzed. Additional histological staining (e.g., Grocott stain) will be performed to detect fungal hyphae.

    Time frame: Through study completion, an average of 3 years

  10. Histological characteristics of IPA using microbiological testing

    Histological characteristics of IPA in critically ill cirrhotic patients will be analyzed. Additional microbiological testing (e.g., Aspergillus PCR) will be performed to detect fungal hyphae.

    Time frame: Through study completion, an average of 3 years

  11. Correlation of pre-mortem data with post-mortem lung tissue findings

    Time frame: Through study completion, an average of 3 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Jul 2027, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2025
First posted
Nov 20, 2025
StartActual
Aug 1, 2025
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07238114
Collaborators
Gilead Sciences
Responsible party
Sponsor
First posted
Nov 20, 2025
Start date
Aug 1, 2025
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Mar 4, 2026

Study contacts

Joost Wauters, MD, PhD
principal investigator · Universitaire Ziekenhuizen KU Leuven

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion